This is a recording of the live webinar presentation on March 28, 2023.

Checkpoint inhibitors are immunomodulatory antibodies used to enhance immune system and have substantially improved outcomes in various malignancies at advanced stages. Programmed cell death receptor 1 (PD-1), programmed cell death ligand 1 (PD-L1) and Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) are the primary targets for checkpoint inhibition. These drugs have a unique spectrum of side effects, termed as irAEs(immune related adverse events).Overall incidence of clinically significant endocrinopathies is approximately 10 percent of patients treated with checkpoint inhibitors; thyroid, pituitary and adrenal glands are most commonly affected. Acute onset type 1 diabetes like presentation is also described as a rare side effect.

Endocrinology input is often necessary in the holistic management of these patients and awareness among the endocrine community is important. This webinar will review the diagnosis and management of these conditions from endocrine point of view.

1. Identify and diagnose immune related adverse endocrine events
2. Interpret the diagnostic tests for immune related adverse endocrine events
3. Manage acute and long term complications of immune related adverse endocrine events

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

Maintenance of Certification (MOC) - if eligible
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported no relevant financial relationships.

The Endocrine Society staff report no relevant financial relationships.